Low Adherence to Upfront and Extended Adjuvant Letrozole Therapy among Early Breast Cancer Patients in a Clinical Practice Setting

Publisher： Karger

E-ISSN： 1423-0232|86|5-6|340-349

ISSN： 0030-2414

Source： Oncology, Vol.86, Iss.5-6, 2014-06, pp. : 340-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extended adjuvant endocrine therapy of early breast cancer

By Chowdhury Simon   Ellis Paul  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1985-1995

Informa Healthcare

Access to resources Recommend Favorite

Optimal adjuvant endocrine therapy for early breast cancer

By Stuart-Harris Robin   Davis Alison  

Women's Health, Vol. 6, Iss. 3, 2010-05 ,pp. : 383-398

Future Medicine

Access to resources Recommend Favorite

Elderly Breast Cancer Patients: Adjuvant Chemotherapy and Adjuvant Endocrine Therapy

By  

Gynäkologisch-geburtshilfliche Rundschau, Vol. 45, Iss. 3, 2005-06 ,pp. : 137-142

Karger

Access to resources Recommend Favorite

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

By Karnon Jonathan  

The European Journal of Health Economics, Vol. 9, Iss. 2, 2008-05 ,pp. : 171-183

Springer Publishing Company

Access to resources Recommend Favorite

Letrozole: advancing hormone therapy in breast cancer

By Lee Rebecca J   Armstrong Anne C   Wardley Andrew M  

Women's Health, Vol. 8, Iss. 6, 2012-11 ,pp. : 611-618

Future Medicine

Access to resources Recommend Favorite